Verition Fund Management
CALA

Verition Fund Management’s Calithera Biosciences, Inc CALA Stock Holding History

Verition Fund Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,846
Closed -$406K – 1458
2020
Q2 		$406K Buy
+3,846
New +$457K 0.01% 677
2015
Q3 		– Sell
-758
Closed -$108K – 776
2015
Q2 		$108K Buy
+758
New +$176K 0.02% 542

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's CALA Position: Q3 2020 in Review

Verition Fund Management sold out of Calithera Biosciences, Inc (CALA) in Q3 2020, closing a stake of 3,846 shares — an estimated $406K sold.

Verition Fund Management first reported a position in CALA in Q2 2015 and held it in 2 quarters. The position peaked at $406K in Q2 2020. 97 funds tracked by Wall St. Rank hold CALA as of Q3 2020.

  • Verition Fund Management reported no remaining Calithera Biosciences, Inc position as of Q3 2020 after selling out during the quarter.
  • Verition Fund Management sold 3,846 Calithera Biosciences, Inc shares in Q3 2020, an estimated $406K.
  • Verition Fund Management first reported a position in Calithera Biosciences, Inc in Q2 2015 and held it in 2 quarters.
  • Verition Fund Management's Calithera Biosciences, Inc position peaked at $406K in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2020.

Based on Verition Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.